Health Discovery Corporation announces successful clinical trial results for new molecular diagnostic test for prostate cancer
Health Discovery Corporation announced the successful clinical trial results for HDC's new molecular diagnostic test for prostate cancer licensed exclusively to Clarient, in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties.
A prostate cancer protein has been identified that could lead to new diagnostic tests and treatments.